Equities
  • Price (EUR)0.232
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+37.28%
  • Beta2.0748
Data delayed at least 15 minutes, as of Feb 27 2026.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

VIVA Biotech Holdings is an investment holding company. The Company has two segments. The Drug Discovery Services segment provides structure-based drug discovery services to biotech and pharmaceutical clients for preclinical innovative drug development. The Contract Design and Manufacturing (CDMO) and Commercialization Services segment is engaged in contract development and manufacturing services for small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, as well as the trading of APIs, intermediates and finished products. The Company conducts business primarily in the United States, China, Europe and other regions.

  • Revenue in HKD (TTM)2.10bn
  • Net income in HKD197.03m
  • Incorporated2008
  • Employees2.09k
  • Location
    VIVA Biotech Holdings735 Ziping RoadZhoupu Town, Pudong New DistrictShanghai 201318ChinaCHN
  • Phone+86 2 160893288
  • Fax+86 2 158243936
  • Websitehttps://www.vivabiotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.